{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T01:37:19Z","timestamp":1773884239042,"version":"3.50.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,10,5]],"date-time":"2024-10-05T00:00:00Z","timestamp":1728086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,5]],"date-time":"2024-10-05T00:00:00Z","timestamp":1728086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Pediatr"],"DOI":"10.1007\/s00431-024-05763-5","type":"journal-article","created":{"date-parts":[[2024,10,5]],"date-time":"2024-10-05T03:31:49Z","timestamp":1728099109000},"page":"5233-5243","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The economic burden of varicella among children in France: a caregiver survey"],"prefix":"10.1007","volume":"183","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6176-0677","authenticated-orcid":false,"given":"Salome","family":"Samant","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3364-4298","authenticated-orcid":false,"given":"Herv\u00e9","family":"Haas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joana","family":"Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David R.","family":"Mink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Pitman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8366-5101","authenticated-orcid":false,"given":"Tanaz","family":"Petigara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8009-805X","authenticated-orcid":false,"given":"Manjiri","family":"Pawaskar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,10,5]]},"reference":[{"issue":"2","key":"5763_CR1","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.vaccine.2014.07.068","volume":"34","author":"WHO","year":"2016","unstructured":"WHO (2016) Varicella and herpes zoster vaccines: WHO position paper, June 2014-Recommendations. Vaccine 34(2):198\u2013199. https:\/\/doi.org\/10.1016\/j.vaccine.2014.07.068","journal-title":"Vaccine"},{"key":"5763_CR2","unstructured":"Lopez A, Harrington T, Marin M, Varicella. Epidemiology of vaccine preventable diseases - Pink Book 2021 [Accessed on 5th August 2024]; 14th Edition:[Available from: https:\/\/www.cdc.gov\/pinkbook\/hcp\/table-of-contents\/chapter-22-varicella.html"},{"key":"5763_CR3","unstructured":"ECDC. Varicella vaccination in the European Union. ECDC Guidance 2015 [Accessed on 5th August 2024]; Available from: https:\/\/www.ecdc.europa.eu\/sites\/default\/files\/media\/en\/publications\/Publications\/Varicella-Guidance-2015.pdf"},{"key":"5763_CR4","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1017\/S0950268817001546","volume":"145","author":"K Bollaerts","year":"2017","unstructured":"Bollaerts K, Riera-Montes M, Heininger U, Souverain U, Verstraeten T, Hartwig S (2017) A systematic review of varicella seroprevalence in European countries before universal childhood immunization: deriving incidence from seroprevalence data. Epidemiol Infect 145:2666\u20132677. https:\/\/doi.org\/10.1017\/S0950268817001546","journal-title":"Epidemiol Infect"},{"key":"5763_CR5","unstructured":"Pierre Louis Institute of Epidemiology and Public Health. Annual Report 2019. Sentinelles - Reseau Sentinelles 2020 [Accessed on 5th August 2024]; Available from: https:\/\/www.sentiweb.fr\/document\/5017"},{"issue":"2","key":"5763_CR6","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1097\/inf.0000000000002233","volume":"38","author":"V Spoulou","year":"2019","unstructured":"Spoulou V, Alain S, Gabutti G, Giaquinto C, Liese J, Martinon-Torres F, Vesikari T (2019) Implementing universal varicella vaccination in Europe: the path forward. Pediatr Infect Dis J 38(2):181\u2013188. https:\/\/doi.org\/10.1097\/inf.0000000000002233","journal-title":"Pediatr Infect Dis J"},{"issue":"3","key":"5763_CR7","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1017\/s0950268802007720","volume":"129","author":"PYHT Bo\u00eblle","year":"2002","unstructured":"Bo\u00eblle PYHT (2002) Varicella in non-immune persons: incidence, hospitalization and mortality rates. Epidemiol Infect 129(3):599\u2013606. https:\/\/doi.org\/10.1017\/s0950268802007720","journal-title":"Epidemiol Infect"},{"issue":"3","key":"5763_CR8","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S1695-4033(03)78170-3","volume":"59","author":"EG P\u00e9rez-Yarza","year":"2003","unstructured":"P\u00e9rez-Yarza EG, Arranz L, Alustiza J, Azkunaga B, Uriz J, Sarasua A, Mendiburu I, Emparanza JI (2003) Hospitalizaciones por complicaciones de la varicela en ni\u00f1os menores de 15 a\u00f1os. Anales de Pediatr\u00eda 59(3):229\u2013233. https:\/\/doi.org\/10.1016\/S1695-4033(03)78170-3","journal-title":"Anales de Pediatr\u00eda"},{"issue":"9","key":"5763_CR9","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1097\/INF.0b013e31829ae263","volume":"32","author":"JG Liese","year":"2013","unstructured":"Liese JG, Cohen C, Rack A, Pirzer K, Eber S, Blum M, Greenberg M, Streng A (2013) The effectiveness of varicella vaccination in children in Germany: a case-control study. Pediatr Infect Dis J 32(9):998\u20131004. https:\/\/doi.org\/10.1097\/INF.0b013e31829ae263","journal-title":"Pediatr Infect Dis J"},{"issue":"S4","key":"5763_CR10","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1093\/infdis\/jiac242","volume":"226","author":"M Marin","year":"2022","unstructured":"Marin M, Lopez AS, Melgar M, Dooling K, Curns AT, Leung J (2022) Decline in severe varicella disease during the united states varicella vaccination program: hospitalizations and deaths, 1990\u20132019. J Infect Dis 226(S4):407\u201315. https:\/\/doi.org\/10.1093\/infdis\/jiac242","journal-title":"J Infect Dis"},{"issue":"12","key":"5763_CR11","doi-asserted-by":"publisher","first-page":"555","DOI":"10.3345\/cep.2021.01564","volume":"65","author":"YH Lee","year":"2022","unstructured":"Lee YH, Choe YJ, Lee J, Kim E, Lee JY, Hong K, Yoon Y, Kim Y-K (2022) Global varicella vaccination programs. Clin Exp Pediatr 65(12):555\u2013562. https:\/\/doi.org\/10.3345\/cep.2021.01564","journal-title":"Clin Exp Pediatr"},{"issue":"3","key":"5763_CR12","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1080\/21645515.2018.1546525","volume":"15","author":"FH Varela","year":"2019","unstructured":"Varela FH, Pinto LA, Scotta MC (2019) Global impact of varicella vaccination programs. Hum Vaccin Immunother 15(3):645\u2013657. https:\/\/doi.org\/10.1080\/21645515.2018.1546525","journal-title":"Hum Vaccin Immunother"},{"issue":"9","key":"5763_CR13","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1080\/14760584.2020.1825947","volume":"19","author":"F Kauffmann","year":"2020","unstructured":"Kauffmann F, Bechini A, Bonanni P, Casabona G, Wutzler P (2020) Varicella vaccination in Italy and Germany - different routes to success: a systematic review. Expert Rev Vaccines 19(9):843\u2013869. https:\/\/doi.org\/10.1080\/14760584.2020.1825947","journal-title":"Expert Rev Vaccines"},{"key":"5763_CR14","unstructured":"INFOVAC, France. Chickenpox [Accessed on 5th August 2024]; Available from: https:\/\/www.infovac.fr\/vaccins\/maladies-evitables\/varicelle"},{"key":"5763_CR15","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/B978-0-323-35761-6.00062-6","volume-title":"Plotkin\u2019s Vaccines","author":"AA Gershon","year":"2018","unstructured":"Gershon AA, Marin M, Seward JF, Plotkin SA, Orenstein WA, Offit PA, Edwards KM (2018) 62\u2014Varicella Vaccines. Plotkin\u2019s Vaccines. Elsevier, Philadelphia, pp 1145\u20131180"},{"key":"5763_CR16","unstructured":"Service-Public.fr, F.R. Leave for sick children in the private sector. 2023 [Accessed on 5th August 2024]; Available from: https:\/\/www.service-public.fr\/particuliers\/vosdroits\/F151?lang=en"},{"issue":"10034","key":"5763_CR17","doi-asserted-by":"publisher","first-page":"2236","DOI":"10.1016\/S0140-6736(16)00580-8","volume":"387","author":"O Nay","year":"2016","unstructured":"Nay O, B\u00e9jean S, Benamouzig D, Bergeron H, Castel P, Ventelou B (2016) Achieving universal health coverage in France: policy reforms and the challenge of inequalities. Lancet 387(10034):2236\u20132249. https:\/\/doi.org\/10.1016\/S0140-6736(16)00580-8","journal-title":"Lancet"},{"key":"5763_CR18","unstructured":"Statista (2021) Distribution of French population as of 2021, by region: Statista. [Accessed on 2021]; Available from: https:\/\/www.statista.com\/statistics\/608761\/population-of-france-by-region\/"},{"issue":"10","key":"5763_CR19","doi-asserted-by":"publisher","first-page":"e0258391","DOI":"10.1371\/journal.pone.0258391","volume":"16","author":"T Launay","year":"2021","unstructured":"Launay T, Souty C, Vilcu AM, Turbelin C, Blanchon T, Guerrisi C, Hanslik T, Colizza V, Bardoulat I, Lemaitre M, Boelle PY (2021) Common communicable diseases in the general population in France during the COVID-19 pandemic. PLoS One 16(10):e0258391. https:\/\/doi.org\/10.1371\/journal.pone.0258391","journal-title":"PLoS One"},{"key":"5763_CR20","doi-asserted-by":"publisher","DOI":"10.1017\/S1744133121000165","author":"OR Zeynep","year":"2021","unstructured":"Zeynep OR, Gandr\u00e9 C, Zaleski I, Steffen M (2021) France\u2019s response to the Covid-19 pandemic: between a rock and a hard place. Health Econ Policy Law. https:\/\/doi.org\/10.1017\/S1744133121000165","journal-title":"Health Econ Policy Law"},{"key":"5763_CR21","doi-asserted-by":"crossref","unstructured":"Gold MR (1996) Cost-effectiveness in health and medicine. Oxford university press.","DOI":"10.1093\/oso\/9780195108248.001.0001"},{"issue":"1","key":"5763_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13561-020-00298-5","volume":"11","author":"X Xu","year":"2021","unstructured":"Xu X, Lazar CM, Ruger JP (2021) Micro-costing in health and medicine: a critical appraisal. Health Econ Rev 11(1):1. https:\/\/doi.org\/10.1186\/s13561-020-00298-5","journal-title":"Health Econ Rev"},{"key":"5763_CR23","unstructured":"Or Z, Gandr\u00e9 C, Sepp\u00e4nen A-V, Hern\u00e1ndez-Quevedo C, Webb E, Michel M, Chevreul K (2023) France: health system review. [Accessed on 5th August 2024]; Available from: https:\/\/iris.who.int\/handle\/10665\/371027"},{"key":"5763_CR24","unstructured":"Maladie LA (2023) Reimbursement of consultations and telemedicine procedures. [cited 2022] [Accessed on 2022]; Available from: https:\/\/www.ameli.fr\/assure\/remboursements\/rembourse\/consultations-telemedecine\/modificationstarifs-consultations-mai-2017"},{"key":"5763_CR25","unstructured":"ScanSante (2014) Applications [cited 2023]. Available from: https:\/\/www.scansante.fr\/applications. Accessed on 5th August 2024"},{"key":"5763_CR26","unstructured":"CLEISS (n.d.) The French Social Security System- Health, maternity, paternity, disability, and death. The French Social Security System [cited 2024]; Available from: https:\/\/www.cleiss.fr\/docs\/regimes\/regime_france\/an_1.html. Accessed on 5th August 2024"},{"issue":"4","key":"5763_CR27","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1097\/INF.0000000000004254","volume":"43","author":"SA Kujawski","year":"2024","unstructured":"Kujawski SA, Casey CS, Haas H, Patel A, Diomatari C, Holbrook T, Pawaskar M (2024) Clinical and economic burden of antibiotic use among pediatric patients with varicella infection in the outpatient setting: a retrospective cohort analysis of real-world data in France. Pediatr Infect Dis J 43(4):393\u2013399. https:\/\/doi.org\/10.1097\/INF.0000000000004254","journal-title":"Pediatr Infect Dis J"},{"issue":"2","key":"5763_CR28","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1080\/14737167.2021.1881484","volume":"21","author":"A Yuasa","year":"2021","unstructured":"Yuasa A, Yonemoto N, LoPresti M, Ikeda S (2021) Productivity loss\/gain in cost-effectiveness analyses for vaccines: a systematic review. Expert Rev Pharmacoecon Outcomes Res 21(2):235\u2013245. https:\/\/doi.org\/10.1080\/14737167.2021.1881484","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"5763_CR29","unstructured":"OECD (2023) Average Annual Wages. [cited 2023]; Available from: https:\/\/stats.oecd.org\/viewhtml.aspx?datasetcode=AV_AN_WAGE&lang=fr. Accessed on 5th August 2024"},{"issue":"s1","key":"5763_CR30","doi-asserted-by":"publisher","first-page":"S58","DOI":"10.1086\/514275","volume":"178","author":"P Saddier","year":"1998","unstructured":"Saddier P, Floret D, Guess H, Durr F, Peyrieux JC, Weber D, Plotkin S (1998) Cost of varicella in France: a study in day care centers. J Infect Dis 178(s1):S58\u2013S63. https:\/\/doi.org\/10.1086\/514275","journal-title":"J Infect Dis"},{"issue":"2","key":"5763_CR31","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.medmal.2005.12.001","volume":"36","author":"C Emery","year":"2006","unstructured":"Emery C, Lan\u00e7on F, Fagnani F, Pechevis M, Durand I, Floret D (2006) Prise en charge de la varicelle et de ses complications en m\u00e9decine ambulatoire en France: l\u2019\u00e9tude ENVOL. Med Mal Infect 36(2):92\u201398. https:\/\/doi.org\/10.1016\/j.medmal.2005.12.001","journal-title":"Med Mal Infect"},{"issue":"3","key":"5763_CR32","doi-asserted-by":"publisher","first-page":"2266225","DOI":"10.1080\/21645515.2023.2266225","volume":"19","author":"I Williame","year":"2023","unstructured":"Williame I, George M, Shah HA, Homer N, Alderson D, Jamet N (2023) Healthcare resource use and costs of varicella and its complications: A systematic literature review. Hum Vaccin Immunother 19(3):2266225. https:\/\/doi.org\/10.1080\/21645515.2023.2266225","journal-title":"Hum Vaccin Immunother"},{"key":"5763_CR33","unstructured":"Francaise R (1989) Order of May 3, 1989 relating to the durations and conditions of eviction, prophylactic measures to be taken with regard to students and staff in public and private teaching and education establishments in the event of contagious diseases, LegiFrance, Editor. France"},{"key":"5763_CR34","unstructured":"Recognizing Chickenpox (2022) [cited 2023]; Available from: https:\/\/www.ameli.fr\/assure\/sante\/themes\/varicelle\/reconnaitre-varicelle-enfant#:~:text=Une%20personne%20est%20contagieuse%2024,s%C3%A8ches%20et%20forment%20une%20cro%C3%BBte. Accessed on 8\/9\/2023"},{"issue":"4","key":"5763_CR35","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1080\/21645515.2018.1559687","volume":"15","author":"LJ Wolfson","year":"2019","unstructured":"Wolfson LJ, Castillo ME, Giglio N, Meszner Z, Molnar Z, Vazquez M, Wysocki M, Altland A, Kuter BJ, Rickard B, Rampakakis E (2019) Varicella healthcare resource utilization in middle income countries: a pooled analysis of the multi-country MARVEL study in Latin America & Europe. Hum Vaccin Immunother 15(4):932\u2013941. https:\/\/doi.org\/10.1080\/21645515.2018.1559687","journal-title":"Hum Vaccin Immunother"},{"issue":"13","key":"5763_CR36","doi-asserted-by":"publisher","first-page":"2678","DOI":"10.1017\/S0950268817001649","volume":"145","author":"JL Walker","year":"2017","unstructured":"Walker JL, Andrews NJ, Mathur R, Smeeth L, Thomas SL (2017) Trends in the burden of varicella in UK general practice. Epidemiol Infect 145(13):2678\u20132682. https:\/\/doi.org\/10.1017\/S0950268817001649","journal-title":"Epidemiol Infect"},{"key":"5763_CR37","unstructured":"Service-Public.fr FR (2023) Complementary health solidarity (ex-CMU-C). [cited 2023]; Available from: https:\/\/www.service-public.fr\/particuliers\/vosdroits\/F10027?lang=en. Accessed on 5th August 2024"},{"key":"5763_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12889-021-12343-x","volume":"21","author":"M Pawaskar","year":"2021","unstructured":"Pawaskar M, M\u00e9roc E, Samant S, Flem E, Bencina G, Riera-Montes M, Heininger U (2021) Economic burden of varicella in Europe in the absence of universal varicella vaccination. BMC Public Health 21:1\u201311. https:\/\/doi.org\/10.1186\/s12889-021-12343-x","journal-title":"BMC Public Health"}],"container-title":["European Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-024-05763-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00431-024-05763-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-024-05763-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T09:23:22Z","timestamp":1730366602000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00431-024-05763-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,5]]},"references-count":38,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["5763"],"URL":"https:\/\/doi.org\/10.1007\/s00431-024-05763-5","relation":{},"ISSN":["1432-1076"],"issn-type":[{"value":"1432-1076","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,5]]},"assertion":[{"value":"22 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This was a non-interventional study involving human subjects and data collection through the survey. The study was approved by an ethics committee, the Committee for the Protection of Persons (Comit\u00e9s de Protection des Personnes Ouest IV \u2013 Nantes, France), per local regulations. The study was performed according to the ethical standards laid down in the\u00a01964 Declaration of Helsinki\u00a0and later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"For the qualitative interviews, participants provided verbal consent before participating and consented to an audio recording of the interview. For the primary survey, after screening, eligible respondents were informed about the study procedures, including the risks\/benefits. They completed an electronic informed consent (non-opposition) form before survey participation, which the IRB approved before use in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Part of these data was presented at the 2023 International Society Pharmacoeconomics and Outcomes Research (ISPOR), Europe conference, Denmark.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Previous presentation"}},{"value":"This study was funded by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. SS, MP, and TP are employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA (MSD), and own stock and\/or hold stock options in Merck & Co., Inc., Rahway, NJ, USA. JS, DM, and RP are employees of ICON Health, which received funding from MSD for this study. Dr. Haas is an employee of Princess Grace Hospital, Monaco, and received an honorarium for this study. He has also worked with pharmaceutical companies such as MSD and Pfizer and received payment from them.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}